GPX4 overexpression in GC is prognostically significant, correlating with advanced disease progression and therapeutic resistance [16], while pharmacologically enhancing GPX4 degradation can restore ferroptosis sensitivity [17]. The gene discussed is GPX4; the disease is gastric cancer.